[
    [
        {
            "time": "2020-11-25",
            "original_text": "复星医药抛近50亿元定增预案 3.25亿用于新冠mRNA疫苗临床及里程碑付款",
            "features": {
                "keywords": [
                    "复星医药",
                    "定增",
                    "新冠",
                    "mRNA疫苗",
                    "临床试验"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药抛近50亿元定增预案 3.25亿用于新冠mRNA疫苗临床及里程碑付款",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2020-11-25",
            "original_text": "阿里健康中期调整净利润大增286.4%；先健科技控股子公司元心科技引入战略投资",
            "features": {
                "keywords": [
                    "阿里健康",
                    "净利润增长",
                    "先健科技",
                    "战略投资"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "阿里健康中期调整净利润大增286.4%；先健科技控股子公司元心科技引入战略投资",
                "Correlation": 7,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-11-26",
            "original_text": "A股头条之上市公司（11.26）",
            "features": {
                "keywords": [
                    "A股",
                    "上市公司"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "A股头条之上市公司（11.26）",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 3,
                "Entity_Density": 2,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-11-25",
            "original_text": "复星医药(02196)：“18复药02”拟转售金额不超过2.6亿元",
            "features": {
                "keywords": [
                    "复星医药",
                    "转售",
                    "债券"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药(02196)：“18复药02”拟转售金额不超过2.6亿元",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-11-25",
            "original_text": "复星医药(600196.SH)：BNI拟与LGVW及其全资子公司ClayMergerSub,Inc.进行合并交易",
            "features": {
                "keywords": [
                    "复星医药",
                    "合并交易",
                    "BNI",
                    "LGVW"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药(600196.SH)：BNI拟与LGVW及其全资子公司ClayMergerSub,Inc.进行合并交易",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-11-25",
            "original_text": "复星医药(02196)拟定增不超过约1.28亿股A股以集资加大对“4+3”研发平台的建设",
            "features": {
                "keywords": [
                    "复星医药",
                    "定增",
                    "研发平台"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药(02196)拟定增不超过约1.28亿股A股以集资加大对“4+3”研发平台的建设",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2020-11-25",
            "original_text": "复星医药(600196.SH)：拟就HLX35与Binacea进行开发合作并就该产品向其授予相关许可权",
            "features": {
                "keywords": [
                    "复星医药",
                    "开发合作",
                    "HLX35",
                    "Binacea"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药(600196.SH)：拟就HLX35与Binacea进行开发合作并就该产品向其授予相关许可权",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-11-25",
            "original_text": "复星医药在江苏启动新冠疫苗二期临床试验，拟招募960人",
            "features": {
                "keywords": [
                    "复星医药",
                    "新冠疫苗",
                    "二期临床试验",
                    "招募"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药在江苏启动新冠疫苗二期临床试验，拟招募960人",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2020-11-25",
            "original_text": "复星医药(02196)和BioNTech(BNTX.US)宣布其新冠候选疫苗BNT162b2将在中国开展二期临床试验",
            "features": {
                "keywords": [
                    "复星医药",
                    "BioNTech",
                    "新冠疫苗",
                    "BNT162b2",
                    "二期临床试验"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药(02196)和BioNTech(BNTX.US)宣布其新冠候选疫苗BNT162b2将在中国开展二期临床试验",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2020-11-25",
            "original_text": "复星医药现1笔大宗交易 共成交538.00万元",
            "features": {
                "keywords": [
                    "复星医药",
                    "大宗交易"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药现1笔大宗交易 共成交538.00万元",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 8
            }
        }
    ]
]